title: [Anticholinergic treatment of overactive bladder syndrome. Is it all the same?].
abstract: Anticholinergic therapy is the first-line therapy for overactive bladder (OAB) syndrome. Especially in the last years, the number of available substances has increased because of the launch of solifenacin, darifenacin, and fesoterodine. Additionally, slow-release and transdermal formulations have led to a large variety of available treatment options. The efficacy of all substances has been proven in randomised, double-blind studies, and reviews and meta-analyses have also underlined the efficacy of all available anticholinergics and have been updated regularly. All available drugs are efficacious for OAB treatment, and clinically relevant differences among them have not been proven consistently. Moreover, age, gender, and the type of OAB (dry vs. wet) seem to lack clinically relevant impact on the efficacy of OAB treatment. The various drugs are similar in tolerability, with the exception of more dry mouth and central nervous effects with slow-release oxybutynin. Knowledge of pharmacokinetic properties of the individual substances is important in order to choose the right therapy for each patient.
authors.affiliation: Praxisklinik Urologie Rhein-Ruhr, Schulstrasse 11, 45468 Mülheim a.d. Ruhr. t.schneider@pur-r.de
authors.forename: T
authors.initials: T
authors.lastname: Schneider
authors.forename: M C
authors.initials: MC
authors.lastname: Michel
mesh_terms: D018680:Cholinergic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D013577:Syndrome; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000517:prevention & control; D014987:Xerostomia / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D018680:Cholinergic Antagonists; D018727:Muscarinic Antagonists